PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells

International Journal of Ophthalmology

Volumn 5, Issue 6, 2012, Pages 675-680

  Cai, Na ^a   Dai, Shun Dong ^a   Liu, Ning Ning ^a   Liu, Li Min ^a   Zhao, Ning ^a   Chen, Lei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Human retinal pigment epithelial cell; PI3K AKT mTORsignal pathway; Proliferativevitreoretinopathy

Indexed keywords

EID: 84894577484     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2012.06.05     Document Type: Article

References (18)

1. Campochiaro PA. Pathogenesis of proliferative vitreoretinopathy. In: Ogden DH, Schachat AP, Murphy RP, Glaser BM, Ryan SJ, editors. Retina. London: C.V. Mosby; 2001. pp. 2221-2227.
2. Eibl KH, Kook D, Priglinger S., Haritoglou C, Yu A, Kampik A., Welge-Lussen U. Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines. Invest Ophthalmol Vis Sci. 2006;47(1):364-370.
3. Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol. 1989;227(6):565-568.
4. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229(5):464-467.
5. Araiz JJ, Refojo MF, Arroyo MH, Leong FL, Albert DM, Tolentino FI Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1993;34(3):522-530.
6. Lee JJ, Park JK, Kim YT, Kwon BM, Kang SG, Yoo YD, Yu YS, Chung H. Effect of 2'-benzoyl-oxycinnamaldehyde on RPE cells in vitro and in an experimental proliferative vitreoretinopathy model. Invest Ophthalmol Vis Sci. 2002;43(9):3117-3124.
7. Eibl KH, Banas B, Schoenfeld CL, May CA, Neubauer AS, Priglinger S, Kampik A., Welge-Lussen U. Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2003;44(8):3556-3561.
8. Rao RD, Buckner JC, Sarkaria JN Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets. 2004;4(8):621-635.
9. Rhoads JM, Niu X, Odle J., Graves LM Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol. 2006;291(3):G510-517.
10. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci. 2005;46(2):454-460.
11. Brown EJ, Albers MW, Shin TB, Ichikawa K., Keith CT, Lane WS, Schreiber SL A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-758.
12. Browne GJ, Proud CG Regulation of peptide-chain elongation in mammalian cell. Eur J Biochem. 2002;269(22):5360-5368.
13. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol. 2004;16(6):564-575.
14. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and rapor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296-1302.
15. Treins C, Giorgetti-Peraldi S, Murdaca J., Monthouël-Kartmann MN, Van Obberghen E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. Mol Endocrinol. 2005;19(5):1304-1317.
16. Zhang B, Cao H, Rao GN 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of P13K-Akt-mTOR-S6K1 signaling. Cancer Res. 2005;65(16):7283-7291.
17. Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol. 2003;13(10):797-806.
18. Xu G, Zhang W, Bertram P., Zheng XF, McLeod H. Pharmacogenomic profiling of the P13K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol. 2004;24(4):893-900.